Charles Schwab’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.46B | Buy |
51,891,636
+1,351,517
| +3% | +$36M | 0.22% | 78 |
|
|
2025
Q4 | $1.26B | Buy |
50,540,119
+410,082
| +0.8% | +$10.3M | 0.2% | 88 |
|
|
2025
Q3 | $1.28B | Buy |
50,130,037
+965,005
| +2% | +$23.8M | 0.2% | 81 |
|
|
2025
Q2 | $1.19B | Buy |
49,165,032
+1,135,457
| +2% | +$26.5M | 0.21% | 84 |
|
|
2025
Q1 | $1.22B | Sell |
48,029,575
-107,429,526
| -69% | -$2.81B | 0.23% | 71 |
|
|
2024
Q4 | $4.12B | Buy |
155,459,101
+25,315,159
| +19% | +$687M | 0.76% | 23 |
|
|
2024
Q3 | $3.77B | Buy |
130,143,942
+12,864,343
| +11% | +$375M | 0.72% | 26 |
|
|
2024
Q2 | $3.28B | Sell |
117,279,599
-4,960,353
| -4% | -$137M | 0.63% | 32 |
|
|
2024
Q1 | $3.37B | Buy |
122,239,952
+17,993,520
| +17% | +$499M | 0.78% | 20 |
|
|
2023
Q4 | $2.99B | Buy |
104,246,432
+8,473,686
| +9% | +$256M | 0.76% | 23 |
|
|
2023
Q3 | $3.16B | Buy |
95,772,746
+9,393,992
| +11% | +$332M | 0.91% | 18 |
|
|
2023
Q2 | $3.15B | Buy |
86,378,754
+2,477,573
| +3% | +$96.4M | 0.9% | 19 |
|
|
2023
Q1 | $3.41B | Buy |
83,901,181
+10,560,702
| +14% | +$456M | 1.04% | 13 |
|
|
2022
Q4 | $3.74B | Buy |
73,340,479
+3,216,573
| +5% | +$154M | 1.21% | 5 |
|
|
2022
Q3 | $3.07B | Buy |
70,123,906
+6,001,894
| +9% | +$292M | 1.1% | 6 |
|
|
2022
Q2 | $3.36B | Buy |
64,122,012
+4,293,163
| +7% | +$219M | 1.17% | 5 |
|
|
2022
Q1 | $3.1B | Buy |
59,828,849
+6,972,650
| +13% | +$362M | 0.93% | 11 |
|
|
2021
Q4 | $3.12B | Sell |
52,856,199
-552,544
| -1% | -$27.4M | 0.92% | 11 |
|
|
2021
Q3 | $2.3B | Sell |
53,408,743
-1,184,631
| -2% | -$52.5M | 0.75% | 17 |
|
|
2021
Q2 | $2.14B | Buy |
54,593,374
+4,018,496
| +8% | +$156M | 0.71% | 18 |
|
|
2021
Q1 | $1.83B | Buy |
50,574,878
+8,565,595
| +20% | +$304M | 0.67% | 18 |
|
|
2020
Q4 | $1.55B | Sell |
42,009,283
-147,466
| -0.3% | -$5.41M | 0.61% | 21 |
|
|
2020
Q3 | $1.47B | Buy |
42,156,749
+151,543
| +0.4% | +$5.31M | 0.68% | 18 |
|
|
2020
Q2 | $1.3B | Sell |
42,005,206
-95,674
| -0.2% | -$3.25M | 0.64% | 23 |
|
|
2020
Q1 | $1.3B | Sell |
42,100,880
-88,334
| -0.2% | -$3.01M | 0.77% | 17 |
|
|
2019
Q4 | $1.57B | Buy |
42,189,214
+1,241,015
| +3% | +$44.2M | 0.84% | 15 |
|
|
2019
Q3 | $1.4B | Buy |
40,948,199
+3,058,078
| +8% | +$111M | 0.82% | 15 |
|
|
2019
Q2 | $1.56B | Buy |
37,890,121
+915,757
| +2% | +$36.4M | 0.95% | 10 |
|
|
2019
Q1 | $1.49B | Buy |
36,974,364
+624,819
| +2% | +$25M | 0.95% | 14 |
|
|
2018
Q4 | $1.51B | Sell |
36,349,545
-721,828
| -2% | -$30M | 1.15% | 7 |
|
|
2018
Q3 | $1.55B | Buy |
37,071,373
+36,365
| +0.1% | +$1.4M | 1.03% | 7 |
|
|
2018
Q2 | $1.27B | Buy |
37,035,008
+402,222
| +1% | +$13.7M | 0.93% | 10 |
|
|
2018
Q1 | $1.23B | Buy |
36,632,786
+220,020
| +0.6% | +$7.56M | 0.96% | 10 |
|
|
2017
Q4 | $1.25B | Buy |
36,412,766
+832,763
| +2% | +$28.4M | 0.99% | 9 |
|
|
2017
Q3 | $1.21B | Buy |
35,580,003
+508,513
| +1% | +$16.3M | 1.05% | 8 |
|
|
2017
Q2 | $1.12B | Buy |
35,071,490
+2,122,583
| +6% | +$66.9M | 1.05% | 8 |
|
|
2017
Q1 | $1.07B | Buy |
32,948,907
+397,783
| +1% | +$12.5M | 1.07% | 6 |
|
|
2016
Q4 | $1B | Buy |
32,551,124
+2,017,526
| +7% | +$61.6M | 1.1% | 6 |
|
|
2016
Q3 | $981M | Buy |
30,533,598
+1,883,717
| +7% | +$63M | 1.15% | 5 |
|
|
2016
Q2 | $957M | Sell |
28,649,881
-319,239
| -1% | -$10.2M | 1.2% | 5 |
|
|
2016
Q1 | $815M | Buy |
28,969,120
+636,290
| +2% | +$18.2M | 1.07% | 7 |
|
|
2015
Q4 | $868M | Buy |
28,332,830
+1,314,235
| +5% | +$41.3M | 1.17% | 5 |
|
|
2015
Q3 | $806M | Sell |
27,018,595
-659,718
| -2% | -$21.2M | 1.19% | 6 |
|
|
2015
Q2 | $881M | Sell |
27,678,313
-1,052,860
| -4% | -$34.3M | 1.22% | 5 |
|
|
2015
Q1 | $948M | Buy |
28,731,173
+241,234
| +0.8% | +$7.67M | 1.33% | 4 |
|
|
2014
Q4 | $842M | Buy |
28,489,939
+1,684,672
| +6% | +$48.3M | 1.26% | 5 |
|
|
2014
Q3 | $752M | Buy |
26,805,267
+1,588,738
| +6% | +$44.6M | 1.24% | 6 |
|
|
2014
Q2 | $710M | Buy |
25,216,529
+1,353,144
| +6% | +$38.6M | 1.19% | 7 |
|
|
2014
Q1 | $727M | Buy |
23,863,385
+2,617,244
| +12% | +$78M | 1.3% | 5 |
|
|
2013
Q4 | $617M | Sell |
21,246,141
-2,147,986
| -9% | -$62.5M | 1.18% | 9 |
|
|
2013
Q3 | $641M | Buy |
23,394,127
+444,145
| +2% | +$12.1M | 1.31% | 6 |
|
|
2013
Q2 | $605M | Buy |
+22,949,982
| New | +$634M | 1.35% | 7 |
|
Other funds holding PFE
VCM
VPM
Charles Schwab's PFE Position: Q1 2026 in Review
Charles Schwab increased its Pfizer (PFE) stake by 2.7% in Q1 2026, buying an estimated $36M and bringing the position to 51,891,636 shares worth $1.46B. The position accounts for 0.22% of the portfolio, ranked #78.
Charles Schwab first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.12B in Q4 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Charles Schwab held 51,891,636 shares of Pfizer worth $1.46B as of Q1 2026.
- Charles Schwab bought 1,351,517 Pfizer shares in Q1 2026, an estimated $36M.
- Pfizer made up 0.22% of Charles Schwab's portfolio in Q1 2026, its #78 holding.
- Charles Schwab first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Charles Schwab's Pfizer position peaked at $4.12B in Q4 2024.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.